Global Cancer Stem Cell Therapy Market Outlook 2020 - Competitive Landscape Report - Research and Markets
DUBLIN, May 4, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Cancer Stem Cell Therapy Market Outlook 2020" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) Recombinant technology has improved significantly in past years due to which better therapeutics are expected to be developed in coming years. Many cancer drugs have been developed by utilization of these techniques. Cancer stem cell therapies are also expected to be developed with its help. They are expected to have superior therapeutic effects as compared to conventional therapeutics. With time, mass production is also expected to improve with improve in technology. Higher production at lower cost will allow the pharmaceutical companies to gain more market shares. They will be able to commercialize highly effective cancer stem cell therapeutics at lesser prices. In this way, they will be able to effectively compete in already overcrowded cancer therapeutics segment across the globe. Utilization of cancer stem cells is expected to play an important role in treatment of various cancers like breast and lung cancer. Other cancers like pancreatic cancer, gastric cancer and other cancers which have been studied to lesser extent are going to have significant boost. For this, they have to identify unique features related to different cancers. Investigators are developing biochips which are expected to identify different kind of cancers. Development of this technology requires significant investments along with development of associated technology. It will allow the investigators to generate result with high confidence levels. Some time is expected to be consumed during development of these biochips. Investigators are looking for biomolecules with therapeutic efficacy that could be used in case of cancer stem cells. Micro RNA has been identified as potential candidate which can effectively counteract the cancer stem cells. Such inhibitors are expected to have high specificity due to which lesser side effects are expected to be developed. Many properties of micro RNAs has yet to be deciphered because their side effects are not known. Concerns related to their effect on normal genes have been raised by several researchers that may hamper normal cellular activities. Most of the work has been done at laboratory levels due to which lots of time is expected to be consumed in their commercialization. Cost of these therapeutics is also a major concern as they will be out of access of several cancer patients. Development of targeted drugs is going to play an important role in development in counteracting cancer stem cell therapy. These drugs are expected to have high specificity due to which normal cells will be spared during treatment. They will prevent the cancerous cells to develop resistance so that they won't become recalcitrant. It will also prevent the development of new cancerous cells in the body. By preventing metastasis, spread of cancer cells in different body parts would be checked. Investigators are developing drug discovery systems which would be able to find new lead molecules for developing cancer stem cell therapies. Only few candidate molecules are able to effectively eliminate cancer stem cells. As a result, significant time is consumed in the development of cancer stem cell therapies. Key Topics Covered: 1. Introduction to Stem Cells 2. Classification of Stem Cells 2.1 Basis of Ability to Differentiate 2.2 Basis of Origin 2.3 Basis of their Source 3. Stem Cell Transplants Classification 3.1 Autologous Stem Cell Transplants 3.2 Allogeneic Stem Cell Transplants 3.3 Syngeneic Stem Cell Transplants 4. Cancer Stem Cell Therapy Mechanism of Action 4.1 Targeting Signaling Pathways 4.1.1 Hedgehog Signaling Pathway 4.1.2 Notch Signaling Pathway 4.1.3 WNT Signaling Pathway 4.2 Targeting Cell Surface Markers 4.3 Targeting miRNA Expression 5. Global Cancer Stem Cell Market Analysis 5.1 Current Market Scenario 5.2 Global Cancer Stem Cell Therapies Pipeline Overview 6. Global Cancer Stem Cell Market Dynamics 6.1 Favorable Market Parameters 6.2 Commercialization Challenges 7. Global Cancer Stem Cell Market Future Outlook 8. Global Cancer Stem Cell Clinical Pipeline by Company & Phase 8.1 Research 8.2 Preclinical 8.3 Clinical 8.4 Phase-I 8.5 Phase-I/II 8.6 Phase-II 8.7 Phase-III 9. Discontinued & No Development of Cancer Stem Cell in Clinical Pipeline by Company & Phase 9.1 Discontinued 9.2 No Development Reported 10. Competitive Landscape 10.1 Aldagen 10.2 Apceth 10.3 Benitec Biopharma 10.4 Celgene Corporation 10.5 Cellonis Biotechnologies 10.6 Caladrius Biosciences 10.7 Commence Bio 10.8 ExCellThera 10.9 Galena Biopharma 10.10 Gamida Cell 10.11 Genexine 10.12 ImmunoCellular Therapeutics 10.13 K-STEMCELL 10.14 Medipost 10.15 Mesoblast 10.16 Novartis 10.17 Nuo Therapeutics 10.18 OncoCyte Corporation 10.19 Pluristem Therapeutics 10.20 ReNeuron 10.21 Sangamo BioSciences 10.22 Takeda 10.23 Vericel Corporation For more information visit http://www.researchandmarkets.com/research/kv65vn/global_cancer
Media Contact: Research and Markets Laura Wood, Senior Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets